Status:
NOT_YET_RECRUITING
Insulin Resistance in Egyptian Patients With Multiple Sclerosis
Lead Sponsor:
Assiut University
Conditions:
Multiple Sclerosis
Insulin Resistance
Eligibility:
All Genders
18-50 years
Brief Summary
The goal of this three-phase interventional study is to determine the prevalence of Insulin resistance in non-diabetic patients with multiple sclerosis in Egypt The main questions it aims to answer a...
Detailed Description
In this longitudinal, three-phase, case-control, interventional study, with 250 patients with multiple sclerosis diagnosed according to the 2017 McDonald's criteria will be enrolled. Frist diagnosis o...
Eligibility Criteria
Inclusion
- seventy patients aged 18-50 years old of both sex fulfilling the revised McDonald's Criteria for diagnosis of multiple sclerosis 2017 of different phenotypes (relapsing-remitting, primary progressive, and secondary progressive), will be recruited during their follow-up visits to our MS unit.
Exclusion
- • Recent MS relapse or use of corticosteroids in the past 3 months
- patients with a systemic disease like diabetes mellitus, hypertension, cardiac disease, liver or renal disease or alcoholic patients
- patients who are on a specific diet.
- patients using any anti-inflammatory drugs, cholesterol-lowering agents, estrogen replacement therapy, steroid therapy or other drugs that could affect the metabolic profile.
- Patients with non-MS demyelinating disorders like NMOSD and MOGAD.
- Patients who failed to commit to regular follow-ups.
Key Trial Info
Start Date :
December 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06017726
Start Date
December 1 2024
End Date
June 1 2027
Last Update
July 30 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.